However, once the FDA declares that the shortage is resolved, compounding pharmacies generally must stop producing identical versions of the medication
Semaglutide, marketed as Ozempic, Wegovy, and Rybelsus, is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management and chronic weight management
4 A widely quoted figure is that semaglutide increases thyroxine exposure by 33%, but that number comes from a study of the tablet form of semaglutide (sold as Rybelsus for type 2 diabetes), not the Wegovy injection
Orforglipron Orforglipron is a once-daily, oral, non-peptide GLP-1 RA (small molecule) which interacts with the GLP-1 receptor in a slightly different manner compared to native GLP-1
Its important for patients to report these symptoms to their healthcare provider for appropriate management